Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmodium vivax liver hypnozoite is a non-replicating, dormant, uninucleate stage of the malaria parasite found within human hepatocytes. Hypnozoites are responsible for latent relapses of malaria, sometimes activating weeks to years after initial infection. They evade most antimalarial therapies and are only eradicated by drugs such as primaquine or tafenoquine, which are contraindicated in certain populations due to toxicity. Hypnozoites are distinguished from developing liver schizonts by unique biomarkers (e.g., LISP2, HAP2) and exhibit specialized host-parasite interaction structures like the tubovesicular network. This dormant stage remains one of the biggest challenges to malaria eradication due to its biology, difficulty of detection, and limited therapeutic options
Primaquine/Tafenoquine: selectively kill hypnozoites through oxidative stress mechanisms and unknown disruption of persistence pathways
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium vivax liver hypnozoite (null).